Clinical Trials in Amherst, New York
37 recruiting
Showing 1–20 of 37 trials
Recruiting
Phase 3
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
Episodic Migraine
Merz Therapeutics GmbH990 enrolled108 locationsNCT07018700
Recruiting
Phase 3
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
Chronic Migraine
Merz Therapeutics GmbH780 enrolled108 locationsNCT07018713
Recruiting
Phase 3
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Chronic Inflammatory Demyelinating Polyneuropathy
Sanofi160 enrolled118 locationsNCT06290141
Recruiting
Phase 2Phase 3
HEALEY ALS Platform Trial - Master Protocol
Amyotrophic Lateral Sclerosis
Merit E. Cudkowicz, MD1,500 enrolled78 locationsNCT04297683
Recruiting
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
Lumbar Spinal Stenosis
Stryker Instruments8,000 enrolled2262 locationsNCT03072927
Recruiting
Phase 3
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Acute Treatment of Migraine
Pfizer600 enrolled64 locationsNCT04743141
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Parkinson's Disease
Hoffmann-La Roche900 enrolled142 locationsNCT07174310
Recruiting
Phase 2Phase 3
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
Focal Epilepsy
Biohaven Therapeutics Ltd.390 enrolled124 locationsNCT06132893
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Alzheimer s Disease
Bristol-Myers Squibb586 enrolled123 locationsNCT06976203
Recruiting
Phase 2
ALTO-207 in Adults With Treatment-resistant Depression (TRD)
Treatment Resistant Depression (TRD)
Alto Neuroscience178 enrolled48 locationsNCT07553637
Recruiting
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
Myasthenia GravisGeneralized Myasthenia Gravis (gMG)Generalized Myasthenia Gravis+3 more
argenx70 enrolled10 locationsNCT07294170
Recruiting
Phase 2
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
Myasthenia GravisGeneralized Myasthenia Gravis (gMG)Generalized Myasthenia Gravis+3 more
argenx70 enrolled9 locationsNCT07284420
Recruiting
Phase 3
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
Early Alzheimers Disease
Annovis Bio Inc.760 enrolled81 locationsNCT06709014
Recruiting
Phase 2
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
ObesityOverweight
Eli Lilly and Company1,217 enrolled53 locationsNCT06143956
Recruiting
Phase 2Phase 3
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
Focal Epilepsy
Biohaven Therapeutics Ltd.390 enrolled174 locationsNCT06309966
Recruiting
Phase 2Phase 3
ACP-204 in Adults With Alzheimer's Disease Psychosis
Alzheimer's Disease Psychosis
ACADIA Pharmaceuticals Inc.1,074 enrolled145 locationsNCT06159673
Recruiting
Not Applicable
Balance4Mobility: Effects of Walkasins Use in Individuals With Peripheral Neuropathy and Balance Problems
Peripheral Neuropathy Due to ChemotherapyPeripheral Neuropathy With Type 2 DiabetesPeripheral Neuropathies+2 more
RxFunction Inc.200 enrolled6 locationsNCT06959277
Recruiting
Phase 2
Clinical Trial on Agitation in Alzheimer's Dementia
Alzheimer DiseaseAggressionAgitation,Psychomotor+2 more
IGC Pharma, LLC164 enrolled30 locationsNCT05543681
Recruiting
Phase 3
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
Chronic Migraine
AbbVie420 enrolled61 locationsNCT06810505
Recruiting
Phase 3
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
Migraine
H. Lundbeck A/S600 enrolled70 locationsNCT05164172